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Cancer cell adhesion to the vascular endothelium is an important step in tumor
metastasis. Thy-1 (CD90), a cell adhesion molecule expressed in activated endothelial
cells, has been implicated in melanoma metastasis by binding to integrins present
in cancer cells. However, the signaling pathway(s) triggered by this Thy-1-Integrin
interaction in cancer cells remains to be defined. Our previously reported data indicate
that Ca2+-dependent hemichannel opening, as well as the P2X7 receptor, are key
players in Thy-1-αVβ3 Integrin-induced migration of reactive astrocytes. Thus, we
investigated whether this signaling pathway is activated in MDA-MB-231 breast cancer
cells and in B16F10 melanoma cells when stimulated with Thy-1. In both cancer cell
types, Thy-1 induced a rapid increase in intracellular Ca2+, ATP release, as well as
cell migration and invasion. Connexin and Pannexin inhibitors decreased cell migration,
implicating a requirement for hemichannel opening in Thy-1-induced cell migration.
In addition, cell migration and invasion were precluded when the P2X7 receptor was
pharmacologically blocked. Moreover, the ability of breast cancer and melanoma cells
to transmigrate through an activated endothelial monolayer was significantly decreased
when the β3 Integrin was silenced in these cancer cells. Importantly, melanoma cells with
silenced β3 Integrin were unable to metastasize to the lung in a preclinical mouse model.
Thus, our results suggest that the Ca2+/hemichannel/ATP/P2X7 receptor-signaling axis
triggered by the Thy-1-αVβ3 Integrin interaction is important for cancer cell migration,
invasion and transvasation. These findings open up the possibility of therapeutically
targeting the Thy-1-Integrin signaling pathway to prevent metastasis.
Keywords: Thy-1 (CD90), integrin, P2X7R, trans-endothelial migration, breast cancer, melanoma, inflammation,
metastasis
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INTRODUCTION
Cancer progression involves vascularization of the primary
tumor, detachment of cells from the tumor matrix, migration,
intravasation, adhesion to the vascular endothelium of target
organs, and extravasation. Intravasation leads tumor cells into
the bloodstream, and extravasation allows the passage of cells
through the endothelium in order to proliferate and form
secondary tumors at distant sites, in a process known as
metastasis (Fares et al., 2020). The word “metastasis” is derived
from Greek and means “change of place.” Thus, cell motility is a
key feature of metastatic cells.
Cell motility involves a series of steps that are required to
permit forward movement (Ridley et al., 2003). The molecular
mechanisms commanding motility of cancer cells are controlled
by environmental cues and signals generated within the tumor
cells. A well-established regulator of cancer cell migration is
intracellular Ca2+, which is controlled by various known ion
channels and signal transduction pathways (Yang et al., 2009).
Despite the wealth of available information relating to the control
of cancer cell migration, gaps in our understanding of this process
at the molecular level still remain (Fares et al., 2020).
Over the last decades, genome-wide association studies
(GWASs) have successfully identified cell adhesion molecules as
one of the most prominent group of genes whose expression is
altered in melanoma and breast cancer cells (Akbani et al., 2015;
Wittkowski et al., 2018). Among these genes, integrins stand out
because they are the receptors that facilitate adhesion, migration,
and invasion of cancer cells.
Once cancer cells enter the bloodstream, they adhere to the
endothelial cells (EC) of blood vessels in target tissues and
then extravasate to form secondary tumors (Fares et al., 2020).
Saalbach and coworkers reported that in primary melanoma,
as well as in subcutaneous metastases, the cell adhesion
molecule of the immunoglobulin superfamily Thy-1 (CD90) is
detectable in EC, but absent in healthy skin and in benign
melanocytic skin lesions (nevi) (Schubert et al., 2013). Another
important step in tumor formation is angiogenesis, which implies
increased expression of vascular endothelial growth factor
(VEGF). Importantly, both VEGF and the proinflammatory
cytokine tumor necrosis factor (TNF; aliases are TNFSF2, TNFA,
and TNF-alpha) are inducers of Thy-1 expression. Thy-1 is
additionally implicated in melanoma metastasis by binding to
αVβ3 Integrin present in cancer cells, both in vitro (Saalbach
et al., 2005) and in vivo (Schubert et al., 2013). Thus, cell-cell
interaction between Thy-1 on activated EC and αVβ3 Integrin
on melanoma cells is an essential step in melanoma metastasis.
So far, adhesion and cell migration induced by the Thy-1-
αVβ3 Integrin interaction has not been studied in cancer cells
other than melanoma. Of note, the signaling pathways triggered
as a consequence of this interaction have not been defined
in cancer cells.
Our group has previously reported on signaling pathways
governing astrocyte migration induced by Thy-1 in a model of
neuron-astrocyte interaction. The neuronal membrane protein
Thy-1 binds to αVβ3 Integrin through a specific domain that
contains an RLD tripeptide. By using Surface Plasmon Resonance
(SPR) technology (Hermosilla et al., 2008) and single-molecule
assay optical mini tweezers (Burgos-Bravo et al., 2018), we
demonstrated a direct interaction between Thy-1 and αVβ3
Integrin, with an affinity in the nM range. Integrin engaged by
Thy-1 triggers astrocyte motility by molecular mechanisms we
have described in detail in the past years (Hermosilla et al.,
2008; Kong et al., 2013; Lagos-Cabré et al., 2019; Leyton et al.,
2019). Signaling cascades triggered by this interaction involve the
activation of phospholipase C gamma (PLCγ), which generates
diacylglycerol and inositol trisphosphate (IP3). IP3 activates
its receptor (IP3R) in the endoplasmic reticulum, triggering
the release of Ca2+ from this intracellular store. Ca2+ is
then required for the opening of Connexin-43 and Pannexin-1
hemichannels and release of ATP, which stimulates the purinergic
P2X7 receptor (P2X7R) to promote Ca2+ entry, thus further
increasing intracellular Ca2+ levels (Henriquez et al., 2011;
Alvarez et al., 2016). Therefore, considering the importance of the
Thy-1 and αVβ3 Integrin interaction in melanoma progression,
relevant questions are: (i) Is Thy-1-Integrin engagement relevant
for the migration of other cancer cells? (ii) What is the molecular
mechanism involved in cancer cell migration downstream of
Thy-1-Integrin interaction? To broaden the relevance of our
findings, these questions were addressed not only in a melanoma
model, but also in breast cancer cells known to express αVβ3
Integrin on their surface.
We show here in MDA-MB-231 human breast cancer cells
and B16F10 mouse melanoma cells that Thy-1 induces migration
and invasion of metastatic cancer cells in a β3 Integrin-dependent
manner, by increasing intracellular Ca2+, hemichannel opening,
ATP release, and P2X7R activation. Additionally, we used
EA.hy926 cells as an EC model and treated these cells with TNF.
Our results indicate that TNF stimulation increases Thy-1 protein
levels, which promotes trans-endothelial migration (TEM) of
breast cancer and melanoma cells in a β3 Integrin-dependent
manner. Finally, we demonstrate in an in vivo mouse model




The anti-Thy-1 antibody was from BD Pharmingen Inc.
(Franklin Lakes, NJ, United States) and anti-Hsp90 antibody,
from Santa Cruz Biotechnology (Santa Cruz, CA, United States).
The anti-β3 Integrin polyclonal antibody was from Millipore
(Burlington, MA, United States) and the secondary anti-mouse
and anti-rabbit antibodies coupled to horseradish peroxidase
were from Bio-Rad Laboratories (Hercules, CA, United States).
Protease inhibitors were from Roche Diagnostics (Risch-
Rotkreuz, Switzerland). The chemiluminescent substrate (EZ-
ECL) and Protein A beads were from Pierce Chemical (Rockford,
IL, United States). The siRNAs -a pool of three siRNAs targeting
β3 Integrin and a scrambled sequence used as a control-
were obtained from Ambion (Austin, TX, United States). All
chemicals were purchased from Sigma-Aldrich (St. Louis, MO,
United States), unless otherwise indicated.
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Cell Cultures
MDA-MB-231 human breast cancer cells (ATCC, #HTB-26) were
cultured in DMEM/F12 medium, B16F10 metastatic murine
melanoma cells (ATCC, #CRL6475) were maintained in RPMI
1640 medium, and EA.hy926 EC (ATCC, #CRL2922) were
cultured in IMEM medium. For all these types of cells, the
medium was supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin/streptomycin. Cells were cultured at 37◦C in
5% CO2. Cell medium and antibiotics were from GIBCO Life
Technologies (Grand Island, NY, United States), and FBS was
from HyClone Laboratories (Logan, UT, United States).
Transfection of Cells
MDA-MB-231 cells and B16F10 melanoma cells were grown for
24 h in complete medium at 50–70% confluency. Transfections
were performed with 30 nM of the siRNA mix against β3 Integrin
(Ambion), control siRNA (Ambion) or GFP as a transfection
control, using the Amaxa Nucleofector system following the
manufacturer’s instructions for the VPI-1006 transfection kit
(Lonza, Cologne, Germany) as reported (Alvarez et al., 2016;
Maldonado et al., 2017). Cell extracts were obtained 48 h post-
transfection and analyzed by western blotting. Alternatively,
transfected cells were used in migration, invasion, TEM, and
metastasis assays, as indicated.
Thy-1-Fc and TRAIL-R2-Fc Preparation
The recombinant proteins Thy-1-Fc and TRAIL-R2-Fc were
obtained as previously described (Leyton et al., 2001; Hermosilla
et al., 2008), and coupled to Protein A for cell stimulation.
These proteins were incubated with Protein A at a 10:1 ratio
for 1 h, at 4◦C with gentle shaking, in phosphate-buffer saline
(PBS), as reported (Henriquez et al., 2011). TRAIL-R2-Fc is a
fusion protein of the receptor for the soluble apoptosis-inducing
ligand, TRAIL-R2 (Schneider, 2000), which is used as a control
for possible non-specific effects caused by the Fc portion of the
Thy-1-Fc fusion protein (Alvarez et al., 2016; Lagos-Cabré et al.,
2017). Prior to each experiment involving Thy-1-Fc or TRAIL-
R2-Fc treatment, cells were serum-starved for at least 30 min in
serum-free medium.
Wound-Healing Assay
Cells were seeded in 24-well plates and grown for 24 h to 70–80%
confluence. Sub-confluent cell monolayers were wounded with a
sterile micropipette tip, washed twice with PBS and left in serum-
free medium for 30 min (time 0 h). MDA-MB-231 cells were
stimulated for 16 h and B16F10 cells were stimulated for 7 h with
4 µg of either Thy-1-Fc or TRAIL-R2-Fc coupled to Protein A
(0.4 µg), in serum-free medium. Where indicated, cells were pre-
incubated for 30 min with either Heptanol (500 µM), Probenecid
(1 mM), or a combination of both inhibitors. Alternatively, cells
were pre-treated for 30 min with A438079 (100 nM) or Apyrase
(3 U/ml); or pre-treated for 1 h with BAPTA-AM (5 µM) or 2-
aminoethoxydiphenyl borate (2-APB, 5 µM). In order to quantify
wound closure, the cell-free area was measured at time zero
and after 7 or 16 h by phase contrast microscopy (Kong et al.,
2013; Alvarez et al., 2016). Considering that reactive astrocytes
share many features with cancer cells (see section “Discussion”),
time, concentration and selection of the drugs used in this and
the other assays, were chosen according to previous studies
performed by our laboratory using reactive astrocytes (Alvarez
et al., 2016; Lagos-Cabré et al., 2017).
Transwell Migration Assay
Assays were performed in Boyden Chambers (Transwell Costar,
Saint Louis, MO, United States, 6.5 mm diameter, 8 µm pore
size), according to the manufacturer’s instructions. Briefly, the
lower surfaces of the inserts were coated with 2 µg/ml fibronectin.
MDA-MB-231 or B16F10 cells (5 × 104) were re-suspended in
serum-free medium and incubated with 4 µg of either Thy-1-Fc
or TRAIL-R2-Fc coupled to Protein A (0.4 µg). Cells were added
to the upper chamber of each insert and serum-free medium was
added to the lower chamber. After 2 h, inserts were removed, and
the cells present on the top chamber were scratched-out. Cells
that migrated to the lower side of the insert membranes were
fixed with 4% paraformaldehyde in PBS and stained with a 0.1%
crystal violet solution in methanol 20% for 2 h at 37◦C. Finally,
membranes were then gently washed, dried at room temperature,
mounted in Mowiol, and cells were counted using an inverted
microscope. At least ten fields were evaluated per experiment to
determine the number of cells that transmigrated.
Invasion Assay
Assays were performed in Matrigel chambers (Matrigel
BD, 6.5 mm diameter, 8 µm pore size), according to the
manufacturer’s instructions. Cells (2 × 105) were prepared in
serum-free medium, stimulated with 4 µg of either Thy-1-Fc
or TRAIL-R2-Fc coupled to Protein A (0.4 µg), and added to
the upper chamber of each insert while serum-free medium
was added to the lower chamber. Alternatively, cells were
pre-incubated for 30 min with Probenecid (1 mM), Heptanol
(500 µM), Apyrase (3 U/ml) or A438079 (100 nM); or pre-
treated for 1 h with BAPTA-AM (5 µM) or 2-APB (5 µM).
After 24 h, inserts were removed, washed with PBS and cells
that migrated to the lower side of the insert membranes were
fixed in cold methanol (1%) for 2 min and then stained with
1% Toluidine Blue for 2 h. Finally, cells were counted using an
inverted microscope.
Measurement of Intracellular Calcium
Kinetics
MDA-MB-231 cells were seeded on 25-mm coverslips (4 × 105
cells) and left to adhere for 24 h. Cells were then incubated
with 5 µM Fluo-4-AM (Life Technologies, Grand Island, NY,
United States) in Ringer solution (155 mM NaCl, 4.5 mM KCl,
2 mM CaCl2, 1 mM MgCl2, 5.56 mM glucose, and 5 mM
Hepes pH 7.4) at 37◦C for 30 min, then washed and left in
the same solution. In addition, cells were pre-incubated with
2-APB (5 µM for 1 h) or Xestospongin C (Xes C, 5 µM for
4 h). During acquisition, cells were stabilized for 2 min before
adding Thy-1-Fc to the cultures. Cells were stimulated with 16 µg
of either Thy-1-Fc or TRAIL-R2-Fc, both coupled to Protein A
(1.6 µg). Images were acquired at 2s intervals with an XM10
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 January 2021 | Volume 8 | Article 592442
fcell-08-592442 December 31, 2020 Time: 16:28 # 4
Brenet et al. Thy-1 (CD90)-αVβ3 Integrin in Metastasis
camera (Olympus Latin America Inc., Miami, FL, United States).
Fluorescence intensity was quantified in 100 cells per condition,
using the ImageJ software (National Institute of Health, Bethesda,
MD, United States).1 Results were expressed as (F-F0)/F0, where
F corresponds to the fold change in fluorescence and F0, to
basal fluorescence.
Lucifer Yellow Uptake
MDA-MB-231 cells were seeded on 25-mm coverslips (4 × 105
cells) and left to adhere for 24 h. Cells were then treated with
the indicated inhibitors, as for calcium measurements, or with
BAPTA-AM (5 µM for 1 h), Probenecid (1 mM for 30 min), or
Heptanol (500 µM for 30 min), prior to stimulation with 16 µg
of either Thy-1-Fc or TRAIL-R2-Fc coupled to Protein A (1.6 µg)
for 10 min. After stimulating the cells, they were incubated at
37◦C with 0.5 mg/ml of Lucifer yellow in Ringer solution for
10 min and then washed twice with the same solution. Lucifer
yellow fluorescence intensity was quantified in 100 cells per
condition in relative units, using the region of interest (ROI)
plugin of the ImageJ software, as reported (Henriquez et al., 2011;
Alvarez et al., 2016). The probe was excited at 458 nm, to quantify
emission between 500 and 530 nm.
Extracellular ATP Measurements
MDA-MB-231 cells (1 × 104) were seeded in 48-well plates.
After 24 h, cells were incubated in serum-free media containing
100 µM of the exonuclease inhibitor ARL-67156 (Santa Cruz
Biotechnology, CA, United States) for 30 min, at 37◦C.
Cells were then stimulated with 8 µg of Thy-1-Fc coupled
to Protein A (0.8 µg) for different time periods. Next,
50 µl of culture medium were recovered and incubated
in the dark with 50 µl of CellTiter-Glo
R©
reaction mix
(Promega, Madison, WI, United States). Luminescence intensity
was determined in a Synergy2 multi-mode reader (Biotek
Instruments, Inc., Winooski, VT, United States) and the
values were interpolated using a calibration curve obtained
with different ATP concentrations (0.01, 0.1, 1, and 10 µM)
(Henriquez et al., 2011).
Trans-Endothelial Migration Assay
EA.hy926 cells (2.5 × 104) were grown to confluency (72 h) on
top of an 8 µm-pore size membrane (Transwell, BD Biosciences)
(Ortiz et al., 2016). Endothelial EA.hy926 cells were pre-treated
with 10 ng/ml of TNF during the last 48 h of the monolayer
formation. MDA-MB-231 or B16F10 cells (5 × 104) were co-
transfected with control siRNA or β3 Integrin siRNA, and GFP
as a transfection control in both cases. Transfected cells were
seeded onto the EA.hy926 cells monolayer. After 16 h of co-
incubation, non-adherent cells were washed away with PBS
and the remaining cells bound to the endothelial monolayer
were fixed with 4% paraformaldehyde in PBS, stained with
DAPI and mounted onto glass slides. Green-labeled cells that
transmigrated through the EC monolayer and the Transwell




B16F10 cells (2 × 106) suspended in 500 µl of physiological
saline solution, were injected intravenously into the tail vein
of C57BL/6 mice. The animals were sacrificed 21 days post-
injection. Lungs were fixed in Feketes solution (Ortiz et al.,
2016) and black metastatic tissue from lung was weighed.
Metastasis was expressed as the percentage of black tissue
mass with respect to total lung mass after fixation of the
tissue. Note that for tumor formation and metastasis assays,
male and female mice were used indifferently. This study was
performed according to the rules and standards established
by the Bioethics Committee on Animal Research at the
Faculty of Medicine, Universidad de Chile (Protocol number
CBA # 0897 FMUCH).
Western Blotting
After treatments, cells were washed with cold PBS and lysed
in 0.2 mM Hepes buffer (pH 7.4) containing 0.1% SDS,
phosphatase inhibitor (1 mM Na3VO4) and a protease inhibitor
cocktail (10 mg/ml Benzamidine, 2 mg/ml Antipain, 1 mg/ml
Leupeptin, and 1 mM PMSF). The lysate was centrifuged at
4◦C for 2 min at 20,000 × g to obtain the supernatants. Total
protein extracts were quantified using the bicinchoninic acid
(BCA) method (Pierce Chemical, Rockford, IL, United States).
Whole cell extracts (50 µg total protein) were separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 10%
gels and then transferred to nitrocellulose. Membranes were
blocked with 5% milk in 0.1% Tween-Tris buffered saline
(TBS) and then probed with anti-Thy-1, anti-Hsp90, or anti-
β3 integrin antibodies. Secondary goat anti-rabbit IgG and goat
anti-mouse IgG antibodies conjugated to horseradish peroxidase
were diluted in 5% milk/TBS. Antibody binding was detected
with the EZ-ECL chemiluminescence kit (Thermo Scientific,
Rockford, IL, United States), using the Discovery 12iC model
chemiluminescence system from Ultralum (Claremont, CA,
United States). The bands obtained were digitized and analyzed
using the ImageJ program.
Statistical Analysis
Results were compared using the Kruskal–Wallis test
and Dunn’s post-test with GraphPad Prism 5 software
(San Diego, CA, United States). The Mann–Whitney U
test was employed for paired groups. The specific test
utilized for the statistical analyses is indicated in the figure
legends. Values averaged from three or more independent
experiments were compared. P values <0.05 were considered
statistically significant.
RESULTS
Thy-1 Promotes Migration and Invasion
of Metastatic Breast Cancer Cells in a β3
Integrin-Dependent Manner
Our previous studies indicate that Thy-1 interacts with
β3 Integrin, inducing astrocyte adhesion and migration
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(Leyton et al., 2001; Hermosilla et al., 2008; Avalos et al.,
2009). Here, we tested whether Thy-1 promotes cell migration
and invasion of metastatic breast cancer cells through its
interaction with β3 Integrin. To this end, the MDA-MB-231
human breast cancer cell line was stimulated with Thy-1-Fc
coupled to Protein A, as reported (Kong et al., 2013), and
migration was evaluated in wound-healing (2D) and Boyden
chamber (3D) migration assays. We found that Thy-1-Fc-
stimulation of cells significantly increased wound closure and
migration in the Boyden chamber assay, while for TRAIL-R2-
Fc-treated [negative control (Alvarez et al., 2016; Lagos-Cabré
et al., 2017)] or non-stimulated (NS) cells, no significant
changes in cell migration were observed (Figures 1A,B and
Supplementary Figures 1A,B). Considering that these assays
were performed in serum-free medium and that the Boyden
chamber assay only took 2 h, changes in cell migration are
not likely due to cell proliferation. These results indicate
that Thy-1 promotes the migration of MDA-MB-231 cells
in vitro.
Enhanced cell invasion is an important process in tumor
metastasis that permits colonization of secondary sites in the
body (Fares et al., 2020). Thus, we assessed cell invasiveness
in a Matrigel assay and found that treatment with Thy-1-Fc
enhanced invasion of breast cancer cells, compared to TRAIL-
R2-Fc-treated or NS controls (Figure 1C). Therefore, Thy-1 not
only promotes migration, but also invasion of breast cancer cells.
We then assessed the requirement of β3 Integrin for breast
cancer cell migration and invasion in cells in which β3
Integrin had been silenced. MDA-MB-231 cells were transfected
with control siRNA or siRNA targeting β3 Integrin, and
two days later they were subjected to Thy-1-Fc stimulation.
Here, we demonstrate that for Thy-1-Fc-stimulated cells with
silenced β3 Integrin protein levels (Figure 1D), wound closure
and migration in the Boyden chamber assay decreased,
compared with control siRNA-transfected cells (Figures 1D,E).
Similar results were observed in the invasion assay; Thy-
1 increased invasion of control siRNA cells, while this
was not observed in cells where β3 Integrin had been
silenced (Figure 1F). Therefore, these results show that Thy-
1 promotes MDA-MB-231 cell migration and invasion in a β3
Integrin-dependent manner.
Thy-1 Stimulation Activates IP3-Receptor
Channels Increasing Intracellular
Calcium Levels Required for
Hemichannel Opening
Thy-1-stimulation of astrocytes triggers an intracellular signaling
pathway that includes activation of PLCγ, production of
IP3, activation of the IP3R, and the consequent release of
calcium (Ca2+) from the endoplasmic reticulum (Figure 2A).
If this mechanism were also relevant in cancer cells, inhibition
of the IP3R should reduce intracellular Ca2+ increases and
the chain of events leading to cell migration. Thus, Ca2+
kinetics induced by Thy-1 were analyzed with or without
prior treatment with IP3R inhibitors. To this end, cytoplasmic
Ca2+ elevation induced by Thy-1-Fc was measured using
the Fluorescent Ca2+ indicator dye (Fluo-4-AM). The Ca2+
signal calculated from the steady-state ratio indicated that
Thy-1 induced a rapid (5-7 min) and sustained intracellular
Ca2+ release in MDA-MB-231 cells, while this was not
observed in cells treated with TRAIL-R2-Fc (Figures 2B,C),
for which Ca2+ levels remained constant. Importantly, the
IP3R inhibitors, 2-aminoethoxydiphenyl borate (2-APB) and
Xestospongin C (Xes C), completely eliminated the rise in
intracellular Ca2+ levels stimulated by Thy-1 (Figure 2D)
supporting a role for the IP3R in the initial release of Ca2+ from
the endoplasmic reticulum.
Intracellular Ca2+ signaling has been associated with ATP
release by the opening of hemichannels (Lagos-Cabré et al.,
2017) and transmembrane diffusion of low molecular weight
dyes has been used to indicate hemichannel opening in
multiple cell types, including MDA-MB-231 cells (Qin et al.,
2002). Thus, we next investigated whether Thy-1 stimulation
induced the opening of hemichannels by increasing intracellular
Ca2+ levels. We performed dye-uptake assays in MDA-MB-
231 cancer cells using the low molecular weight fluorescent
dye Lucifer yellow (457 Da). After stimulating the cells with
Thy-1-Fc or TRAIL-R2-Fc for 5 min, we found that Thy-
1-Fc induced Lucifer yellow uptake. However, this was not
the case when cells were pre-incubated with an intracellular
Ca+2 chelator, the cell permeable BAPTA-acetoxymethyl ester
(BAPTA-AM) (Figure 2E). Moreover, the IP3R inhibitors 2-
APB and Xestospongin C prevented Lucifer yellow uptake
promoted by Thy-1-Fc (Figure 2F). Taken together, our results
indicate that Thy-1 induces intracellular release of Ca2+ through
IP3R activation, thereby increasing Ca2+ levels necessary for
hemichannel opening.
Thy-1-Induced Cell Migration and
Invasion Require ATP Release via
Hemichannel Opening and the Activation
of the P2X7 Receptor
We next evaluated whether Thy-1-stimulated MDA-MB-231
breast cancer cell migration/invasion would follow the sequence
of events we have previously described for reactive astrocytes
(Figure 3A; Alvarez et al., 2016; Lagos-Cabré et al., 2017),
where elevated Ca2+ leads to hemichannel opening and
ATP release. These increased levels of extracellular ATP
would then promote cell migration and invasion through
the activation of the P2X7R. To test this hypothesis, cells
were stimulated with Thy-1-Fc for different time periods
and extracellular ATP levels were measured in a colorimetric
assay. We observed that treatment with Thy-1-Fc induced
ATP release after 5 min of stimulation (Figure 3B). To
assess whether hemichannels participated in Thy-1-induced
ATP release, we used hemichannel blockers. The Pannexin
inhibitor, Probenecid, the Connexin blocker, Heptanol, or
a combination of both, significantly decreased extracellular
ATP levels induced by Thy-1-Fc stimulation (Figure 3C).
In addition, pre-treatment with Probenecid, Heptanol or a
mixture of both, inhibited Lucifer yellow uptake in MDA-
MB-231 cells stimulated with Thy-1-Fc (Figure 3D). The
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FIGURE 1 | Thy-1 induces migration and invasion of MDA-MB-231 cells in a β3 Integrin-dependent manner. (A) Wound-healing assay in non-stimulated (NS),
MDA-MB-231 cells, or cells treated with TRAIL-R2-Fc or Thy-1-Fc. The graph shows the quantitative analysis of cell migration after 16 h of treatment. Wound
closure values (%) were obtained by estimating the cell-free area at time point 0 and after 16 h for every sample. (B) Transwell cell migration of MDA-MB-321 cells.
Non-stimulated (NS) cells and cells stimulated with the indicated treatments were allowed to migrate for 2 h through the inserts pre-coated on the lower side with
fibronectin (2 µg/ml). Migrating cells were visualized by crystal violet staining on the lower side of the inserts. Data were normalized to NS cells and are shown as the
average number of cells from 30 different fields per independent experiment. (C) MDA-MB-231 cells were incubated as indicated in panel (B), then added to Matrigel
inserts, and allowed to invade for 24 h. Invasion was visualized by toluidine blue and cells were counted using an inverted microscope. Data averaged from cells
counted in 20 different fields/experiment were normalized to values obtained in the NS condition. (D–F) Experiments were repeated as in panel (A–C), respectively,
using MDA-MB-231 cells transfected with control siRNA or β3 Integrin siRNA. Quantification of the wound-healing assay (D), the Transwell migration assay (E), and
the cell invasion assay (F) of MDA-MB-231 cells, transfected and stimulated as indicated. Data shown represent the average of cells counted in 20–30 different fields
from each independent experiment, normalized to the values obtained with the NS condition. Values shown in all graphs represent the mean ± SEM from three
independent experiments. *p < 0.05; **p < 0.01, ***p < 0.001.
combination of both inhibitors resulted in a more significant
effect than that of the individual compounds alone. Importantly,
wound closure and invasion of breast cancer cells were also
precluded in cells pre-treated with these hemichannel blockers
(Figures 3E,F). Next, we tested whether P2X7R activation
was necessary for Thy-1-induced breast cancer cell migration
and invasion. Here, MDA-MB-231 cells were pretreated with
the nucleotidase enzyme, Apyrase, or the P2X7R antagonist
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FIGURE 2 | Thy-1 opens IP3-receptor channels, inducing intracellular Ca2+ increase and hemichannel opening in MDA-MB-231 cells. (A) Scheme of the αVβ3
Integrin-triggered signaling pathway activated by Thy-1, which leads to intracellular Ca2+ release and hemichannel opening through the activation of PLCγ,
generation of IP3 and activation of the IP3R. (B) Representative microphotographs of intracellular fluorescence in MDA-MB-231 cells loaded with Fluo4-AM (green) at
time point = 0 and after 5 min of treatment with Thy-1-Fc or TRAIL-R2-Fc. (C,D) Intracellular Ca2+ kinetics of Fluo4-AM-loaded MDA-MB-231 cells treated with
Thy1-Fc or TRAIL-R2-Fc (C) or stimulated with Thy1-Fc after pre-treating them with 2-APB (5 µM for 1 h) or Xestospongin C (5 µM for 4 h) (D). Time point = 2 min
on the graph corresponds to the moment when Thy-1 or TRAIL-R2-Fc was added to the cells in culture. Points in the graphs are mean ± SEM values obtained from
three independent experiments. (E,F) Quantification of Lucifer yellow uptake in MDA-MB-231 cells pre-incubated with vehicle (0.001% DMSO in PBS) or BAPTA-AM
(5 µM) for 1 h (E), or pre-incubated with vehicle (0.001% ethanol in PBS for 1h), 2-APB, 5 µM for 1 h or Xestospongin C, 5 µM for 4 h (F), and then stimulated with
Thy-1-Fc. Values shown in the graph correspond to the mean fluorescence intensity (mean ± SEM) normalized to the control (TRAIL-R2-Fc condition), obtained from
three independent experiments. ***p < 0.001.
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FIGURE 3 | Thy-1-induced migration/invasion requires ATP release through hemichannels and the activation of the P2X7 receptor in MDA-MB-231 cells.
(A) Schematic representation of the Thy-1-induced activation of the Ca2+/hemichannel opening/ATP release/P2X7R signaling pathway that initiates cell migration.
(B) Time-dependent release of extracellular ATP in MDA-MB-231 cells induced by Thy-1-Fc during 20 min of stimulation. Quantification of: (C) Extracellular ATP
release, (D) Lucifer yellow uptake, (E) Wound closure, and (F) Invasion of cells treated for 30 min with the vehicle (0.001% ethanol in PBS), the Pannexin-blocking
drug Probenecid (1 mM) and/or the Connexin-blocking drug Heptanol (500 µM), and then stimulated with Thy-1-Fc for 5 min (C), 15 min (D), 16 h (E), or 24 h (F).
Quantification of panel (G) Wound closure and (H) Invasion of MDA-MB-231 cells pretreated for 30 min with the vehicle (PBS), Apyrase (3 mU) or the P2X7R inhibitor
A438079 (100 nM), and then stimulated with Thy-1-Fc for the times indicated in panels (E,F), respectively. Data shown were normalized to values obtained with the
TRAIL-R2-Fc condition used as a control. Values shown in all graphs represent the mean ± SEM from three independent experiments. ns = non-significant.
*p < 0.05; **p < 0.01, ***p < 0.001.
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(A438079), and then stimulated with Thy-1-Fc. We found
that the incubation with Apyrase precluded Thy-1-Fc-induced
migration and invasion, indicating a requirement for ATP
(Figures 3G,H). The same effect was observed after incubating
cells with A438079 (Figures 3G,H). Altogether, these findings
indicate that ATP released through hemichannels leads to
the activation of the P2X7R, and that these signaling events
are essential for breast cancer cell migration and invasion
induced by Thy-1.
Trans-Endothelial Migration of Cancer
Cells Depends on Thy-1 Upregulation
and Its Interaction With β3 Integrin
Trans-endothelial migration is a process that is required for
tumor cells to extravasate from the vascular system and
invade a specific tissue. Here, we investigated the function
of β3 Integrin expression in TEM of cancer cells. TEM
experiments were assayed on EA.hy926 cells, an immortalized
hybrid of HUVEC and the A549 human lung carcinoma
line. EA.hy926 is one of the most commonly used and best
characterized EC lines, which exhibits many endothelium-
specific properties and forms capillary-like structures in matrigel
(Bauer et al., 1992). We first established a monolayer of
EA.hy926 cells and then tested for monolayer permeability
at different time periods (24, 48, and 72 h), as previously
reported by our group (Ortiz et al., 2016). Indeed, after
72 h in culture, the dye was no longer able to permeate
the cell monolayer.
We then evaluated Thy-1 expression in EA.hy926 cells treated
or not with TNF (10 ng/ml) and found that it was enhanced by
TNF treatment at 24, 48, and 72 h, indicative of EC activation at
these time periods, reaching a maximum after 48 h of treatment
(Figure 4A). To evaluate the effect of β3 Integrin on MDA-MB-
231 adhesion to the endothelial monolayer, the breast cancer cells
were co-transfected with control siRNA or β3 Integrin siRNA,
and GFP as a transfection control in both cases. Transfected
cells were seeded onto a monolayer of EA.hy926 cells, pretreated
or not with TNF (48 h), and allowed to transmigrate across
the monolayer for 16 h. The ability of MDA-MB-231 cells
to transmigrate through an EA.hy926 monolayer substantially
increased when EA.hy926 cells were activated with TNF and was
significantly reduced when the cells were transfected with β3
FIGURE 4 | Trans-endothelial migration of MDA-MB-231 and B16F10 cells depends on Thy-1 interaction with β3 Integrin. (A) Thy-1 expression in EA.hy926 cells not
treated with TNF (−) or treated with TNF during 24, 48, and 72 h. Heat Shock Protein 90 (Hsp 90) was used as a loading control. Trans-endothelial migration (TEM)
of panel (B) MDA-MB-231 and (C) B16F10 cancer cells co-transfected with control siRNA (scrambled) or β3 Integrin siRNA and GFP, left untreated or treated with
TNF (10 ng/ml, 48h). In both experiments, EA.hy926 cells were seeded on the Transwell inserts and an impermeable cell monolayer was allowed to form for 72 h.
Transfected cancer cell lines (Control siRNA or β3 integrin siRNA) were added to the EA.hy926 monolayer in each insert. Cancer cells were then allowed to penetrate
the EA.hy926 monolayer for 16 h. Cells that transmigrated through the endothelial monolayer were counted on the lower side of the Transwell membrane. Values in
the graph correspond to the average TEM normalized to the control siRNA condition. Values shown in both graphs are the means ± SEM from three independent
experiments. *p < 0.05; **p < 0.01, ***p < 0.001.
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Integrin siRNA (Figure 4B). Importantly, TNF treatment for 48 h
during the formation of the monolayer of EA.hy926 cells did not
affect monolayer permeability (Supplementary Figure 2).
Because Thy-1 has also been implicated in melanoma
metastasis by binding to integrins present in cancer cells
(Schubert et al., 2013), we performed the TEM assay in B16F10
melanoma cells. Similar results were obtained when these
metastatic B16F10 cells were employed; that is, TNF activation
of the EA.hy926 monolayer favored TEM of B16F10 cells, but
not when their β3 Integrin levels were reduced with siRNA
(Figure 4C). Taken together, these results indicate that high
levels of Thy-1 are required to promote TEM in a β3 Integrin-
dependent manner.
Thy-1-Induced Melanoma Cell Migration
and Invasion Occur Through a β3
Integrin/Ca2+/Hemichannel/ATP/P2X7R
Signaling Pathway
We then tested the involvement of β3 Integrin in Thy-1-induced
melanoma cell migration and invasion by transfecting B16F10
melanoma cells with control siRNA or β3 Integrin siRNA, and
then stimulating them with Thy-1-Fc. First, we corroborated that
Thy-1-Fc, but not TRAIL-R2-Fc, induced migration and invasion
of non-transfected B16F10 cells or cells transfected with control
siRNA (Figures 5A,B). We also transfected B16F10 cells with β3
Integrin siRNA and observed that the Thy-1-Fc effect on their
migration/invasion was dependent on the presence of β3 Integrin
(Figures 5A,B).
The Thy-1-β3 Integrin interaction induces cell migration
through a Ca2+/P2X7R signaling axis in astrocytes (Alvarez
et al., 2016; Lagos-Cabré et al., 2017) and in MDA-MB-231
breast cancer cells (the present study), but whether melanoma
metastasis was also dependent on Thy-1-β3 Integrin binding
was unknown. Thus, we evaluated the participation of this
signaling pathway in Thy-1-induced melanoma migration
and invasion. First, the role of intracellular Ca2+ increase in
melanoma cell migration and invasion was tested by treating
B16F10 cells with BAPTA-AM or 2-APB, and then stimulating
them with Thy-1-Fc. We found that these treatments precluded
Thy-1-Fc-induced melanoma cell migration and invasion
(Figures 5C,D). The results indicate that intracellular Ca2+
release is a necessary event for melanoma cell migration/invasion
mediated by Thy-1, and that melanoma cell migration requires
IP3R activation.
We also assessed hemichannel opening, ATP release and
P2X7R activation in B16F10 melanoma cell migration and
invasion, using the same approach as described above for
MDA-MB-231 breast cancer cells. Indeed, pre-treatment of
B16F10 cells with Probenecid and/or Heptanol (Figures 5E,F),
Apyrase or A438079 (Figures 5G,H), all inhibited the
migration/invasion of B16F10 cells, indicating the participation
of hemichannels, extracellular ATP and P2X7R in melanoma cell
migration/invasion.
Altogether, these results indicate that β3 Integrin is necessary
for Thy-1-induced melanoma cell migration and invasion and
that the molecular mechanisms triggered downstream of the
Thy-1-β3 Integrin interaction include the Ca2+/P2X7R signaling
axis that we previously described in astrocytes (Alvarez et al.,
2016; Lagos-Cabré et al., 2017) and now show here for
breast cancer cells.
Silencing of β3 Integrin Suppresses
Melanoma Cell Metastasis in vivo
Using a syngenic in vivo mouse model, we next determined
whether the silencing of β3 Integrin expression in B16F10 cells
sufficed to suppress metastasis. Non-transfected B16F10 cells
or cells transfected with control siRNA or β3 Integrin siRNA
were injected into the tail vein of C57BL/6 mice (Figure 6A).
Mice were sacrificed 21 days post injection and the lung tumor
mass was visualized and weighed. Dark black melanomas were
observed in the lungs of mice injected with non-transfected or
control siRNA-transfected cells, while almost no black nodules
were detectable in the lungs of mice injected with β3 Integrin
siRNA-transfected cells (Figure 6B), where β3 Integrin was
knocked-down (Figure 6C). We then quantified the lung tumor
mass and found that there was no significant difference between
mice injected with wild type B16F10 cells and mice injected
with control siRNA-transfected cells; in both cases, tumor
mass was equivalent to 40% of the lung mass (Figure 6D).
However, for mice injected with cells transfected with β3 Integrin
siRNA, almost no tumors were detectable (Figure 6D), clearly
indicating that β3 Integrin plays a key role in metastasis
in vivo.
DISCUSSION
Increasing evidence points toward the involvement of Thy-
1 in the regulation of cancer cell progression and metastasis
(Sauzay et al., 2019). Furthermore, elevated expression of Thy-
1 on blood vessel and lymphatic EC has revealed that Thy-
1 participates in hematogenic and lymphogenic metastasis of
melanoma cells in vivo (Schubert et al., 2013). Here, we
show that Thy-1 induces migration and invasion of metastatic
MDA-MB-231 and B16F10 cancer cells, and when upregulated
in an activated EA.hy926 EC monolayer, promotes TEM of
these breast cancer and melanoma cells in a β3 Integrin-
dependent manner. We also show that β3 Integrin-triggered
downstream signaling includes the release of Ca2+, hemichannel
opening, ATP release, and P2X7R activation. Most importantly,
silencing of β3 Integrin in melanoma cells (this paper) or
injection of wild type B16F10 cells in Thy-1 knock-out mice
(Schubert et al., 2013) abolish melanoma lung metastasis in vivo,
indicating that disruption of the Thy-1-αVβ3 Integrin interaction
precludes melanoma metastases. Moreover, results obtained in
the TEM assays, as well as in in vivo experiments, where
cells were transiently transfected with β3 Integrin siRNA and
injected two days after transfection, suggest that the Thy-1-
αVβ3 Integrin binding is important in an early step of the
metastatic process.
Thy-1 expression is abnormally elevated in melanoma EC
(Schubert et al., 2013). Intriguingly, Thy-1 is also found in
malignant tumors, such as liver, esophageal, gastric, gallbladder,
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FIGURE 5 | Thy-1 induces B16F10 melanoma cell migration and invasion through the β3 Integrin/Ca2+/hemichannel/ATP/P2X7R signaling pathway. (A,B)
Non-transfected B16F10 cells and cells transfected with control siRNA or β3 Integrin siRNA were non-stimulated (NS), treated with TRAIL-R2-Fc or stimulated with
Thy-1-Fc, and evaluated in wound closure (A) and invasion (B) assays. (C–H) B16F10 cells were non-stimulated (NS), treated with TRAIL-R2-Fc or pretreated with
the vehicle (0.001% DMSO in PBS, 1 h), BAPTA-AM (5 µM, 1 h) or 2-APB (5 µM, 1 h) (C,D); or pretreated for 1 h with the vehicle (0.001% ethanol in PBS), the
Pannexin-blocking drug Probenecid (1 mM) or the Connexin-blocking drug Heptanol (500 µM), or a mixture of both drugs (E,F); or pretreated for 30 min with the
vehicle (PBS), Apyrase (3 mU) or the P2X7R inhibitor A438079 (100 nM), and then stimulated with Thy-1-Fc for 7 h, in order to measure wound closure (C,E,G) or
24 h, to assess invasion (D,F,H). Values in the graph correspond to the area (as% of wound closure) at 7 h compared to Time = 0; and to the number of cells
(invasion) normalized to the NS, or TRAIL-R2-Fc-treated conditions. Values shown in all graphs represent the mean ± SEM from three independent experiments.
*p < 0.05; **p < 0.01; ***p < 0.001.
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FIGURE 6 | Silencing of β3 Integrin suppresses melanoma cell metastasis in vivo. (A) C57BL/6 mice were injected into the tail vein with non-transfected B16F10
cells (WT) or cells transfected with control siRNA or β3 Integrin siRNA. (B) Representative images of mouse lungs at 21 days post injection of WT or transfected
B16F10 cells. (C) Quantification of tumor mass in lungs from mice treated with the indicated B16F10 cells. Values in the graph correspond to the percentage of
tumor mass respect to total lung mass. ns = non-significant, ***p < 0.001.
and lung cancer (reviewed in Kumar et al., 2016), where
Thy-1 is likely to act as a tumor promoter. In contrast, Thy-1
expression is reduced in other types of cancer, such as ovarian
(Abeysinghe et al., 2003), and nasopharyngeal cancer (Hong
et al., 2005), suggesting that in some tumor cells, Thy-1 may
also act as a tumor suppressor. Thus, the role of Thy-1 in cancer
seems ambiguous, whereby tumor promoting or suppressing
activities appear to depend on the cancer cell type and tumor
microenvironment. Of note, our reported data in astrocyte-
neuron communication have shown that the interaction between
Thy-1 and αVβ3 Integrin occurs both in cis and in trans (Leyton
et al., 2019). The present study focuses on the effect of Thy-1
binding in trans with the αVβ3 Integrin. However, considering
that Thy-1 is reportedly present in MDA-MB-231 breast cancer
cells (Wang et al., 2015), the Thy-1-integrin interaction in cis
could also occur in these cells. In breast cancer cells, Thy-1
interaction in cis is likely to play a regulatory role, maintaining
integrins inactive; whereas in trans, Thy-1 triggers a signaling
cascade downstream of the integrin in the cancer cell, indicating
that it leads to integrin activation. This issue of cis versus trans
Thy-1-integrin interaction, and their effects on cells has been
recently reviewed in Leyton et al. (2019).
Reactive astrocytes share many features with glioma cells.
They proliferate, migrate, exhibit anchorage-independent growth
and form neurospheres (Lang et al., 2004), express growth
factors (such as VEGF), upregulate IL-6 signaling, and express
elevated levels of Vimentin, Nestin, and Sox2. Levels of proteins
involved in migration, proliferation, and dedifferentiation are
also enhanced in reactive astrocytes (reviewed in Yang et al.,
2013). In addition, and considering the importance of integrins
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in adhesion and migration of astrocytes (Kong et al., 2013) and
cancer cells (McCabe et al., 2007; Pan et al., 2018), the similarities
reported here between the mechanisms involved in migration of
reactive astrocytes and tumor cells is not surprising.
Among the different integrins, β1 and β3 Integrins have
essential roles in the progression of different cancer types
[reviewed in Pan et al. (2018)]. Specifically, the expression of
αVβ3 Integrin is associated with tumor progression of human
malignant melanoma (Saalbach et al., 2005) and metastatic
growth of breast cancer cells in the brain (Lorger et al., 2009).
Furthermore, αVβ3 Integrin is an indicator of increased lymph
node or bone metastasis and decreased patient survival in
pancreatic, prostate, and breast cancer (Pan et al., 2018).
Different β Integrin subunits participate in the regulation of
the malignant phenotype by mediating tumor cell interactions
with specific extracellular matrix proteins of the tumor
microenvironment. Knockdown of the β3 Integrin subunit was
shown to reduce primary tumor growth and inhibit pancreatic
cancer metastasis (Grzesiak et al., 2011). β1, β3 and β6 Integrin
subunits are upregulated in human prostate cancer cells, which
express αVβ3 Integrin (reviewed in Goel et al., 2008), and the
β3 and β5 subunits are differentially expressed in breast cancer
cell lines (Lautenschlaeger et al., 2013). Most importantly, the
analysis of colorectal cancer samples by immunohistochemistry
has revealed increased levels of β3 Integrin expression in tumors
at stage III and IV, compared with those at stages I and II
(Lei et al., 2011).
By silencing β3 expression in melanoma cells, we demonstrate
in our study that the β3 Integrin subunit plays a key role in
in vivo metastasis. Besides inhibition of metastasis, loss of β3
Integrin may correlate with loss of tumorigenic morphology, as
reported in breast cancer cells (Sesé et al., 2017). Accordingly,
knockdown of endogenous β3 decreases anchorage-independent
growth and metastasis of pancreatic cells, which may account
for the enhanced malignancy associated with αVβ3 Integrin
expression in many tumors (Desgrosellier et al., 2009). Given the
expression levels of β3 Integrin in many types of cancer cells, it
emerges as a potentially interesting therapeutic target. However,
relying only on this integrin subunit to evaluate the status
of a patient would not be sufficient. Prognosis and treatment
should consider, for example, the association between β3 and
β1 Integrins to increase the effectiveness of targeted therapy
approaches (Pan et al., 2018). Furthermore, β3 Integrin is critical
for the communication between tumor cells and stromal cells, like
fibroblasts and EC, and exhibits a cancer-promoting function via
these interactions with the tumor microenvironment (Zhu et al.,
2019). Therefore, future studies are required to understand the
multiple roles of β3 Integrin in cancer, in order to progress in the
design of effective targeting strategies.
On the other hand, genetic interference and pharmacological
targeting of the αV Integrin subunit might also contribute to
the reduction of tumor cell function observed after silencing
β3 Integrin. In different breast cancer lines, for example, the
αV antagonist GLPG0187 inhibits invasion and metastasis in
zebrafish or a mouse xenograft model (Li et al., 2015). Due to
the co-expression of αV and β3 subunits in cancer cells, future
studies are needed to characterize their roles in specific types of
cancer. Even though integrins have been the focus for therapeutic
intervention for over three decades and despite some therapeutic
advances (reviewed in Janiszewska et al., 2020), their highly
complex biology has often delayed drug development.
Cell migration and invasion are critical steps for the
metastatic dissemination of cancer cells and metastasis (reviewed
in Fares et al., 2020), which constitutes the major cause of
death in cancer patients. Here, we describe how the interaction
between Thy-1 (CD90) on activated ECs and β3 Integrin on
melanoma and breast cancer cells promotes their migration,
TEM, and invasion, via a signaling mechanism that involves
Ca2+/hemichannel/ATP/P2X7R activation. Noteworthy,
blocking any step of this signaling cascade inhibits cell migration,
indicating the existence of a sequence of events that leads
to cell motility. To move, cells create protrusions in the
direction of the motion at one end, while retracting similar
projections at the other end. It is a cyclical process coordinated
by various proteins on the cell surface, which includes the
integrin/hemichannels/P2X7R proteins and the intracellular
Ca2+ increase. This cytosolic Ca2+ elevation is likely to occur at
specific times and locations to modulate cell motility (reviewed
in Lagos-Cabré et al., 2019).
Regulation of cancer cell migration by different signal
transduction pathways has been previously reported. For
example, the EP4 receptor, the predominant PGE2 receptor
subtype in HT-29 and HCA-7 human colon cancer cell lines,
activates PI3K and induces Ca2+ influx from the extracellular
space through Orai1, resulting in ERK phosphorylation and
migration of oral cancer cells (Osawa et al., 2020). The PI3K-AKT
and Ras-ERK pathways regulate migration, invasion, and many
other characteristics of cancer cells through multiple downstream
effectors, establishing complex signaling networks that pose
a huge challenge for the development of anticancer drugs
[reviewed in Sever and Brugge (2015)]. Another possibility is that
the P2Y2R, a GPCR that possesses an RGD domain and binds to
activated αVβ3 Integrin, could trigger downstream PLC enzyme
activation, accounting for the Ca2+ released from intracellular
stores, as reported in the present manuscript, and in astrocytes
(reviewed in Henriquez et al., 2011). This possibility has never
been tested in our model systems. Instead, P2X7R involvement
has been demonstrated in this manuscript and in our previous
reports using astrocytes (Henriquez et al., 2011; Alvarez et al.,
2016). Thus, it is possible that the sustained Ca2+ signal reported
in our studies is due to Ca2+ uptake through ATP-activated
P2X7R, and that there is an undetectable first, sharp peak of Ca2+
released through the IP3R present in the endoplasmic reticulum.
In addition, many studies have shown that the P2X7R and the
tumor microenvironment play an important role in regulating
the growth, apoptosis, migration and invasion of tumor cells
(reviewed in Zhang et al., 2020). Involvement of the P2X7R
has been described in tamoxifen-resistant MCF-7 breast cancer
cells, where activity of this receptor seems to be restricted to
cell migration and metastasis, rather than cell proliferation (Park
et al., 2019). Therefore, in the cancer cells used in our study, the
P2X7R might be selectively activated to induce cell migration.
Importantly, P2X7R is present on the surface of most tumor
cells (Yang et al., 2016), activates different signaling pathways
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(Deng et al., 2017), and promotes tumor angiogenesis (Gómez-
Villafuertes et al., 2016). Therefore, reducing the expression level
of P2X7R and the use of P2X7R agonists and antagonists may
unveil the specific mechanism by which P2X7R participates in
migration of cancer cells and other aspects of tumorigenesis.
Moreover, the effect of P2X7Rs on cell migration is still a
matter of controversy, likely due to differences in local ATP
concentrations. Supporting this idea is the fact that the BzATP
agonist, a pharmacological agent used to stimulate P2X7R,
has been shown to induce, as well as inhibit cell migration,
depending on the concentration of the agonist used (Wei et al.,
2008; Mankus et al., 2011; Zhou et al., 2014). Additionally, our
previous studies show that BzATP alone is sufficient to mimic
the effects of Thy-1-induced signaling downstream of αVβ3
Integrin engagement (Henriquez et al., 2011; Alvarez et al., 2016).
Perhaps, the continuous release of ATP helps maintain high
local ATP concentrations, to activate P2X7R and the downstream
signal transduction events required for the cyclic process of cell
migration (Alvarez et al., 2016). A similar autocrine loop has been
suggested to exist for the highly motile PC-9 human lung cancer
cells, which show continuous ATP release and constitutive P2X7R
activation in in vitro culture conditions (Takai et al., 2014).
Moreover, the movement of dendritic cells has been attributed to
P2X7R signaling in an autocrine loop that activates the opening
of Pannexin-1, leading to additional ATP release (Sáez et al.,
2017). This autocrine mechanism is very relevant for our studies,
because we also reported a role for Pannexin-1 in ATP release in
cancer cells (this study) and in astrocytes (Alvarez et al., 2016;
Lagos-Cabré et al., 2017, 2018).
In summary, our study uncovers the molecular mechanisms
by which cancer cell β3 integrin engagement of Thy-1 in EC
triggers cancer cell migration and invasion, and in doing so,
identifies various candidates that could be targeted to treat cancer
patients, perhaps in a combined multiple-target therapy.
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Supplementary Figure 1 | Thy-1-induced migration of MDA-MB-231 cells. (A)
Wound-healing assay in non-stimulated (NS), or cells treated with TRAIL-R2-Fc
(negative control) or Thy-1-Fc. Representative images of wound-healing assays in
pseudocolor. Green cells: MDA-MB-231 cultures at 0 h. Red cells: MDA-MB-231
at 16 h after treatment. (B) Representative images of MDA-MB-231 cell migration
in Boyden chamber. Non-stimulated (NS) cells and cells with TRAIL-R2-Fc or
Thy-1-Fc treatments were allowed to migrate for 2 h through the inserts
pre-coated on the lower side with fibronectin (2 µg/ml). Migrating cells were
visualized by crystal violet staining on the lower side of the inserts. Magnification
bar = 100 µm.
Supplementary Figure 2 | In vitro endothelial cell permeability assay. The
permeability of endothelial cell monolayers was evaluated by testing the ability of
such monolayers to retain Blue dextran dye. EA.hy926 cells were grown to
confluency (72 h) on top of an 8 µm-pore size membrane. Cells were pre-treated
with 10 ng/ml of TNF during the last 48 h of the monolayer formation. The
permeability of the monolayer was evaluated by adding complete medium with
Blue dextran (10 mM) to the upper chamber and complete medium to the lower
chamber. Then, after 30 min, the absorbance was determined at 618 nm. The
absence of changes on the lower chamber was taken as being indicative of a
sealed cell monolayer.
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